Business Insider7d
Corbus Pharmaceuticals (CRBP) Gets a Buy from William Blair
William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened today at $7.10. Effectively assess a stock's ...
Business Insider7d
Corbus Pharmaceuticals (CRBP) Gets a Buy from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday ...
Seeking Alpha1mon
Corbus Pharmaceuticals falls after trial data for lead asset
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of ...
ETF Daily News9d
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday
Shares of NASDAQ CRBP opened at $6.79 on Monday. Corbus Pharmaceuticals has a twelve month low of $6.54 and a twelve month high of $61.90. The firm has a market cap of $82.70 million, a P/E ratio ...
Nasdaq28d
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. As of February 19, 2025, the average ...